Loading...
•
Mar 31
Twist Bioscience Q2 2025 Earnings Report
Twist Bioscience reported its Q2 2025 financial results with improved margins and narrowing losses.
Key Takeaways
Twist Bioscience delivered $92.8 million in revenue for Q2 FY25, with a significant improvement in gross margin to 49.6% and a reduced adjusted EBITDA loss of $14.8 million, indicating strong progress toward profitability.
Revenue reached $92.8M, at the top end of guidance.
Gross margin rose to 49.6%, showing strong operational improvement.
Adjusted EBITDA loss narrowed to $14.8M, trending toward breakeven.
All segments reported double-digit YoY revenue growth.
Twist Bioscience
Twist Bioscience
Twist Bioscience Revenue by Segment
Revenue by Segment
SynBio Revenue
CapyFin.comNGS Revenue
CapyFin.comBiopharma Revenue
CapyFin.com Forward Guidance
Twist projects revenue growth in Q3 and Q4 FY25, aiming to surpass 50% gross margin and continue reducing EBITDA losses.
Positive Outlook
- Q3 FY25 revenue projected between $94M–$97M
- Gross margin expected to exceed 50% in Q4 FY25
- Strong NGS performance to continue
- Biopharma revenue expected to reach $6M
- Full-year revenue guided to $372M–$379M
Challenges Ahead
- Adjusted EBITDA still forecast to remain negative
- High SG&A expenses remain a drag on profitability
- Gross margin in Q3 may be below 50%
- Macroeconomic risks and R&D investments may affect cash burn
- Profitability timeline dependent on execution of margin expansion plans
Revenue & Expenses
Visualization of income flow from segment revenue to net income